2-哌嗪基-5-吡啶硼酸 | 1003043-67-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-哌嗪基-5-吡啶硼酸
• 中文别名: 2-哌嗪并吡啶-5-硼酸
• 英文名称: (6-(piperazin-1-yl)pyridin-3-yl)boronic acid
• 英文别名: (6-piperazin-1-ylpyridin-3-yl)boronic acid
• CAS: 1003043-67-1
• 化学式: C₉H₁₄BN₃O₂
• 分子量: 207.04
• InChiKey: JICCVPKLABRNMW-UHFFFAOYSA-N

物化性质

• 沸点：
  469.7±55.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.83
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  68.6
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Piperazinopyridine-5-boronic acid
Synonyms: 6-(Piperazin-1-yl)pyridin-3-ylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Piperazinopyridine-5-boronic acid
CAS number: 1003043-67-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H14BN3O2
Molecular weight: 207.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-哌嗪基-5-吡啶硼酸 在 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium carbonate 、 N,N-二异丙基乙胺 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 N,N-二甲基乙酰胺 、 水 为溶剂， 反应 48.33h， 生成 (S)-6-(1,3-dimethyl-1H-pyrazol-4-yl)-4-(6-(4-(3-methoxypyrrolidine-1-carbonyl)piperazin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
  [FR] COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINES COMME INHIBITEURS DE LA KINASE RET

  摘要：

  本文提供了一般式I的化合物及其立体异构体和药用可接受的盐或溶剂，其中A、B、D、E、X1、X2、X3和X4的含义如规范中所述，这些化合物是RET激酶的抑制剂，可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括由RET激酶介导的疾病或紊乱。

  公开号：

  WO2017011776A1

文献信息

• [EN] OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS<br/>[FR] COMPOSÉS OXAZOLIDINONE ET PROCÉDÉS D'UTILISATION DE CES DERNIERS EN TANT QU'AGENTS ANTIBACTÉRIENS
  申请人：MERCK SHARP & DOHME

  公开号：WO2017066964A1

  公开（公告）日：2017-04-27

  The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosiscomprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or apharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

  本发明涉及式(I)的噁唑烷酮化合物及其药学上可接受的盐，其中A、E和R1如本文所定义。本发明还涉及包含本发明至少一种噁唑烷酮化合物的组合物。该发明还提供了抑制分枝杆菌细胞生长的方法，以及通过给予治疗有效量的本发明的噁唑烷酮和/或其药学上可接受的盐，或包含该化合物和/或盐的组合物来治疗结核分枝杆菌感染的方法。
• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINE EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018071447A1

  公开（公告）日：2018-04-19

  Provided herein are compounds of the Formula I and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文件提供了公式I的化合物以及立体异构体和药用可接受的盐或溶剂化物，其中A、B、X1、X2、X3、X4、环D和E具有说明书中给出的含义，它们是RET激酶的抑制剂，可用于治疗和预防可通过RET激酶抑制剂治疗的疾病，包括与RET相关疾病和失调。
• Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives
  作者：Takeshi Fukuda、Riki Goto、Toshihiro Kiho、Kenjiro Ueda、Sumie Muramatsu、Masami Hashimoto、Anri Aki、Kengo Watanabe、Naoki Tanaka

  DOI：10.1016/j.bmcl.2017.10.031

  日期：2017.12

  we report the design, synthesis and structure–activity relationships (SAR) of a series of 4,6-disubstituted indazole compounds as hepcidin production inhibitors. The optimization study of multi-kinase inhibitor 1 led to the design of a potent and bioavailable hepcidin production inhibitor, 32 (DS28120313), which showed serum hepcidin-lowering effects in an interleukin-6-induced acute inflammatory

  铁调素已成为系统性铁稳态中的主要调节分子，其抑制作用可能是治疗慢性疾病性贫血（ACD）的有利策略。在这里，我们报告了一系列作为铁调素生产抑制剂的4,6-二取代的吲唑化合物的设计，合成和结构-活性关系（SAR）。对多激酶抑制剂1的优化研究导致了一种有效的，可生物利用的铁调素生产抑制剂32（DS28120313）的设计，该抑制剂在白介素6诱导的急性炎症小鼠模型中显示出降低血清铁调素的作用。
• Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia
  作者：Jing Liu、Chao Yang、Catherine Simpson、Deborah DeRyckere、Amy Van Deusen、Michael J. Miley、Dmitri Kireev、Jacqueline Norris-Drouin、Susan Sather、Debra Hunter、Victoria K. Korboukh、Hari S. Patel、William P. Janzen、Mischa Machius、Gary L. Johnson、H. Shelton Earp、Douglas K. Graham、Stephen V. Frye、Xiaodong Wang

  DOI：10.1021/ml200239k

  日期：2012.2.9

  small molecule Mer kinase inhibitors. Several pyrazolopyrimidine derivatives effectively inhibit Mer kinase activity at subnanomolar concentrations. Furthermore, the lead compound shows a promising selectivity profile against a panel of 72 kinases and has excellent pharmacokinetic properties. We also describe the crystal structure of the complex between the lead compound and Mer, opening new opportunities

  异位 Mer 表达促进促生存信号传导，并有助于儿童急性淋巴细胞白血病 (ALL) 的白血病发生和化学抗性。因此，Mer 激酶抑制剂可能会促进白血病细胞死亡，并进一步充当化学增敏剂，提高当前 ALL 方案的疗效并降低毒性。我们已应用基于结构的设计方法来发现新型小分子 Mer 激酶抑制剂。几种吡唑并嘧啶衍生物在亚纳摩尔浓度下有效抑制 Mer 激酶活性。此外，先导化合物对一组 72 种激酶显示出有希望的选择性，并具有出色的药代动力学特性。我们还描述了先导化合物和 Mer 之间复合物的晶体结构，为进一步优化和新模板设计开辟了新的机会。
• Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines
  作者：László Kékesi、Anna Sipos、Gábor Németh、János Pató、Nóra Breza、Ferenc Baska、László Őrfi、György Kéri

  DOI：10.1016/j.bmcl.2013.09.005

  日期：2013.11

  novel pyrido[2,3-b]pyrazines were synthesized as potential antitumor agents for erlotinib-resistant tumors. Known signal inhibitor compounds from our Nested Chemical Library were tested in phenotypic assays on erlotinib-sensitive PC9 and erlotinib-resistant PC9-ER cell lines to find a compound class to be active on erlotinib resistant cell lines. Based on the screening data, novel pyrido[2,3-b]pyrazines

  合成了一系列新型的吡啶并[2,3- b ]吡嗪类化合物，作为抗厄洛替尼耐药肿瘤的潜在抗肿瘤药。我们对巢式化学文库中已知的信号抑制剂化合物进行了表型分析，以对厄洛替尼敏感的PC9和耐厄洛替尼的PC9-ER细胞系进行了测试，以找出在耐厄洛替尼的细胞系中具有活性的化合物类别。根据筛选数据，设计合成了新型吡啶并[2,3- b ]吡嗪。探索了杂芳族部分在7位上的取代基位置的影响以及吡啶并吡嗪核心2位未取代的重要性。化合物7n的IC 50抑制PC9的值为0.09μM，抑制PC9-ER的值为0.15μM。我们发现这些结构的一些先导化合物克服了对厄洛替尼的耐药性，这可能成为有望与EGFR T790M突变抗NSCLC的候选药物。这些新型化合物克服厄洛替尼耐药性的作用机制中涉及的信号网络仍有待阐明。